Clin2
NCT07044609Possibly a fitNot yet recruiting

Study of Onyda XR for ADHD and ODD in children

Attention-deficit/Hyperactivity DisorderOppositional Defiant Disorder in Children

Part of Mental health clinical trials.

This trial tests a new extended-release medication called Onyda XR (clonidine) in children aged 6 to 12 who have both ADHD and Oppositional Defiant Disorder. The goal is to see if it helps with symptoms like inattention, hyperactivity, and defiant behavior, and if it is safe.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
162 people
Ages
6 years to 12 years
Study type
Interventional

Who can take part

  • Your child must be between 6 and 12 years old.
  • Your child must have both ADHD and Oppositional Defiant Disorder (ODD) diagnosed by a doctor.
  • You and your child must be able to speak, read, and understand English.
  • Your child must stop taking stimulant medications 7 days before starting the study and other non-stimulant ADHD meds 14 days before.
  • Your child cannot have certain other serious mental health conditions like bipolar disorder, psychosis, autism, or severe anxiety.
  • Your child cannot have a history of heart problems, seizures (except febrile seizures before age 5), or high or low blood pressure.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03781765Recruiting· Phase 4
Testing stimulant vs non-stimulant ADHD treatments in young kids

This study compares stimulant and non-stimulant ADHD medicines in kids who have not taken ADHD medication before. It also studies how these treatments affect brain “reward” processes, which may be linked to substance-use risk.

New York, New York
NCT04781140Recruiting· Phase 4
Viloxazine trial for preschool kids with ADHD

This study tests whether viloxazine extended-release can reduce ADHD symptoms in children ages 4–5. It also checks safety in preschool-age kids, including heart and nervous-system side effects.

Saraland, Alabama
NCT03420339Recruiting· Phase 4
Stimulant medicine effects on disruptive behavior in kids

This trial studies how ADHD stimulant medicine may change disruptive behaviors like aggression, tantrums, or refusing instructions. It may help clinicians understand whether stimulant dosing is supporting both ADHD symptoms and day-to-day behavior.

Iowa City, Iowa
NCT07710014Not yet recruiting· Phase 4
Testing Foquest for ADHD in adults 65 and older

This trial tests if the medication Foquest can help treat ADHD symptoms in adults aged 65 and older. It aims to see if it's safe and effective for this age group.

NCT06577779Recruiting· Phase 4
Testing Jornay PM for adult ADHD symptoms into the evening

This study tests if Jornay PM, a long-acting ADHD medication, helps control symptoms, focus, and emotions throughout the day and into the early evening in adults with ADHD. It is an open-label study, meaning everyone knows they are getting the medication, and then they are randomly assigned to different observation groups.

New York, New York
NCT06248229Recruiting· Phase 4
Testing Dyanavel XR for fatigue in adults with ADHD

This trial tests whether the medication Dyanavel XR (a long-acting amphetamine) can help reduce fatigue in adults with ADHD. It is for people who have both ADHD and significant tiredness, and who are not currently taking stimulant ADHD drugs.

Rochester Hills, Michigan

Hear when a new ADHD trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.